Back to Browse Journals » Open Access Rheumatology: Research and Reviews » Volume 4

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

Authors Murakami M, Tomiita M, Nishimoto N

Published Date July 2012 Volume 2012:4 Pages 71—79

DOI http://dx.doi.org/10.2147/OARRR.S21969

Received 11 February 2012, Accepted 21 March 2012, Published 5 July 2012

Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto1
1Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan

Abstract: Systemic juvenile idiopathic arthritis is one of the common rheumatic diseases in childhood and characterized by spiking fever, evanescent skin rash, lymphadenopathy, hepatosplenomegaly, and serositis, in addition to arthritis. Children with systemic juvenile idiopathic arthritis often show growth retardation and developmental abnormality, as well as macrophage activation syndrome, a life-threatening complication. Overproduction of interleukin-6 is pathologically responsible for the systemic inflammatory manifestations and abnormal laboratory results with systemic juvenile idiopathic arthritis. Thus, tocilizumab, a humanized antihuman interleukin-6 receptor antibody, has been developed as a therapeutic agent for the disease. A series of clinical studies have demonstrated the excellent efficacy and safety of tocilizumab for patients with active disease. Tocilizumab was approved for systemic juvenile idiopathic arthritis in Japan in 2008 and in the European Union and the United States in 2011.

Keywords: systemic juvenile idiopathic arthritis, tocilizumab, antihuman interleukin-6 receptor antibody, biologics

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Management strategies for fibromyalgia

Le Marshall KF, Littlejohn GO

Open Access Rheumatology: Research and Reviews 2011, 3:47-51

Published Date: 13 July 2011

Certolizumab in the long-term treatment of rheumatoid arthritis

Khan A, Scott DL

Open Access Rheumatology: Research and Reviews 2011, 3:63-71

Published Date: 26 August 2011

Prevalence of periprosthetic osteolysis after total hip replacement in patients with rheumatic diseases

Perez Alamino R, Casellini C, Ba┼łos A, Schneeberger EE, Gagliardi SA, Maldonado Cocco JA, Citera G

Open Access Rheumatology: Research and Reviews 2012, 4:57-62

Published Date: 6 June 2012

H-2g, a glucose analog of blood group H antigen, mediates monocyte recruitment in vitro and in vivo via IL-8/CXCL8

Rabquer BJ, Hou Y, Ruth JH, Luo W, Eitzman DT, Koch AE, Amin MA

Open Access Rheumatology: Research and Reviews 2012, 4:93-98

Published Date: 19 September 2012

Retrospective analysis of the clinical course of patients treated for polymyalgia

Do-Nguyen D, Inderjeeth CA, Edelman J, Cheah P

Open Access Rheumatology: Research and Reviews 2013, 5:33-41

Published Date: 26 April 2013

Prioritizing the patient: optimizing therapy in rheumatoid arthritis. Results of a patient questionnaire in northern Germany

Wollenhaupt J, Ehlebracht-Koenig I, Groenewegen A, Fricke D

Open Access Rheumatology: Research and Reviews 2013, 5:51-67

Published Date: 15 May 2013